Literature DB >> 35687355

Bio-nano scale modifications of melittin for improving therapeutic efficacy.

Mostafa Akbarzadeh-Khiavi1,2, Mitra Torabi2, Amir-Hossein Olfati3, Leila Rahbarnia4, Azam Safary5.   

Abstract

INTRODUCTION: Melittin (MLT), a natural membrane-active component, is the most prominent cytolytic peptide from bee venom. Remarkable biological properties of MLT, including anti-inflammatory, antimicrobial, anticancer, anti-protozoan, and antiarthritic activities, make it an up-and-coming therapeutic candidate for a wide variety of human diseases. Therapeutic applications of MLT may be hindered due to low stability, high toxicity, and weak tissue penetration. Different bio-nano scale modifications hold promise for improving its functionality and therapeutic efficacy. AREAS COVERED: In the current review, we aimed to provide a comprehensive insight into strategies used for MLT conjugations and modifications, cellular delivery of modified forms, and their clinical perspectives by reviewing the published literature on PubMed, Scopus, and Google Scholar databases. We also emphasized the MLT structure modifications, mechanism of action, and cellular toxicity. EXPERT OPINION: Developing new analogs and conjugates of MLT as a natural drug with improved functions and fewer side effects is crucial for the clinical translation of this approach worldwide, especially where the chemicals and synthetic drugs are more expensive or unavailable in the healthcare system. MLT-nanoconjugation may be one of the best-optimized strategies for improving peptide delivery, increasing its therapeutic efficacy, and providing minimal nonspecific cellular lytic activity. [Figure: see text].

Entities:  

Keywords:  cellular toxicity; mechanism of action; melittin; modification; nanoconjugation; natural peptide

Mesh:

Substances:

Year:  2022        PMID: 35687355     DOI: 10.1080/14712598.2022.2088277

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   5.589


  1 in total

1.  Rational design of an anti-cancer peptide inhibiting CD147 / Cyp A interaction.

Authors:  Zahra Maani; Safar Farajnia; Leila Rahbarnia; Elaheh Zadeh Hosseingholi; Nazli Khajehnasiri; Parisa Mansouri
Journal:  J Mol Struct       Date:  2022-09-16       Impact factor: 3.841

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.